Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
33.24
+1.51 (4.76%)
At close: Jun 26, 2026, 4:00 PM EDT
33.24
0.00 (0.00%)
After-hours: Jun 26, 2026, 5:25 PM EDT
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
| Name | Position |
|---|---|
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director |
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | CEO, President & Executive Director |
| Mr. Chris Deluzio | Executive Vice President of Sales Enterprise Operations |
| Mr. Douglas F. Kling | Chief Operating Officer |
| Mr. Matthew Philippe | Executive VP & Head of Investor Relations |
| Mr. Mayur Amrat Somaiya | Chief Financial Officer |
| Mr. Michael F. Marino Esq. | Chief Legal Officer & Corporate Secretary |
| Ms. Juliette Audet M.B.A., M.Sc. | Chief Strategy & Business Officer |
| Ms. Louise Kooij | Chief Accounting Officer |
| Ms. Maryellen McQuade | Chief People Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-05 | S-8 | nams-20260605.htm |
| 2026-06-03 | 8-K | nams-20260602.htm |
| 2026-05-07 | 8-K | nams-20260507.htm |
| 2026-05-07 | 10-Q | nams-20260331.htm |
| 2026-05-06 | DEF 14A | nams-20260506.htm |
| 2026-05-06 | ARS | nams_2025_10-k_ars.pdf |
| 2026-04-24 | 8-K | nams-20260420.htm |
| 2026-04-20 | PRE 14A | nams-20260420.htm |
| 2026-03-02 | 8-K | nams-20260302.htm |
| 2026-02-18 | S-8 | nams-20260218.htm |